You just read:

FDA Advisory Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated With Halozyme Enhanze Technology

News provided by

Halozyme Therapeutics, Inc.

Mar 29, 2017, 12:44 ET